Envestnet Portfolio Solutions Inc. Takes $543,000 Position in TG Therapeutics, Inc. $TGTX

Envestnet Portfolio Solutions Inc. acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 15,089 shares of the biopharmaceutical company’s stock, valued at approximately $543,000.

Several other large investors also recently made changes to their positions in TGTX. Ameritas Advisory Services LLC acquired a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $25,000. Golden State Wealth Management LLC boosted its holdings in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 433 shares during the last quarter. SVB Wealth LLC acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at approximately $37,000. Brooklyn Investment Group boosted its holdings in shares of TG Therapeutics by 2,159.2% in the 1st quarter. Brooklyn Investment Group now owns 1,604 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 1,533 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of TG Therapeutics by 16.2% in the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 290 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.64% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on TGTX shares. The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price objective for the company in a report on Thursday, July 10th. HC Wainwright initiated coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price target on the stock. B. Riley increased their price target on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.

TG Therapeutics Stock Up 0.3%

Shares of NASDAQ TGTX opened at $35.22 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. TG Therapeutics, Inc. has a 52 week low of $22.61 and a 52 week high of $46.48. The stock has a market capitalization of $5.59 billion, a P/E ratio of 95.19 and a beta of 1.97. The stock’s fifty day moving average is $32.52 and its 200 day moving average is $35.00.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the prior year, the firm earned $0.04 EPS. The business’s revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.